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Abstract
The aim of this study was to evaluate the pathophysiological role and the prognostic significance of pulmonary artery compliance
(CPA), a measure of right ventricular pulsatile afterload, in cardiogenic shock. We retrospectively included 91 consecutive patients
with cardiogenic shock due to primary left ventricular failure, monitored with a pulmonary artery catheter within the first 24 h.
CPA was calculated as the ratio of stroke volume to pulmonary artery pulse pressure, and we determined whether CPA predicted
mortality and whether it performed better than other pulmonary hemodynamic variables. The overall in-hospital mortality in our
cohort was 27%. Survivors and nonsurvivors had comparable left ventricular ejection fraction, systolic, diastolic and mean pul-
monary artery pressure, transpulmonary gradient, diastolic pressure gradient, and pulmonary vascular resistance at 24 h.
In contrast, CPA was the only pulmonary artery variable significantly associated with mortality in univariate and multivariate
analyses. Mortality increased from 4.5% at the highest quartile of CPA (3.6–6.5 mL/mmHg) to 43.5% at the lowest quartile
(0.7–1.7 mL/mmHg). In 64 patients with a PAC inserted immediately upon admission, we calculated the trend of CPA
between admission and 24 h. This trend was positive in survivors (þ0.8 1.3 ml/mmHg) but negative in nonsurvivors
(0.1 1.0 mL/mmHg). The lower CPA in nonsurvivors was associated with more severe right ventricular systolic dysfunction.
In conclusion, a reduced compliance of the pulmonary artery promotes right ventricular dysfunction and is independently
associated with mortality in cardiogenic shock. Future studies should evaluate the impact on pulmonary arterial compliance
and right ventricular afterload of therapies used in cardiogenic shock.
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Introduction
Cardiogenic shock (CS) is a clinical syndrome due to pri-
mary cardiac dysfunction resulting into a state of arterial
hypotension and end-organ hypoperfusion in the absence of
hypovolemia, mainly related to acute coronary syndrome
and associated with high mortality.1 The role of advanced
hemodynamic monitoring with a pulmonary artery catheter
(PAC) in CS remains controversial. Although its use is
recommended to guide therapy in patients in whom intra-
cardiac filling pressures cannot be determined from clinical
assessment (Grade IC),2 randomized studies failed to report
significant benefit of PAC on the outcome of critically ill
patients, although no study specifically focused on CS
patients.3
It must be underscored that some important information
provided by PAC has not been taken into consideration
when considering its usefulness in the field of CS. PAC
allows the evaluation of both pulmonary vascular resistance
(PVR) and pulmonary arterial compliance (CPA), two major
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components of right ventricle (RV) afterload.4 PVR repre-
sents the steady component of RV afterload, while CPA
describes its pulsatile component. CPA can be evaluated by
the ratio of stroke volume (SV) to pulmonary pulse pressure
(PP),5 although this method slightly overestimates CPA, as it
does not consider the fraction of SV flowing towards the
periphery during systole.4 The product of PVR and CPA
defines the time constant (RC time, ) of the pulmonary
circulation.6 These variables may be crucial to properly
evaluate the hemodynamic consequences of CS. Indeed,
the passive transmission of elevated left ventricular (LV)
filling pressure to the pulmonary circulation results in a
stiffening of the pulmonary arterial tree, which leads to a
reduced CPA and a decreased RC time,
7,8 increasing pulsa-
tile RV afterload. This in turn could precipitate RV-arterial
uncoupling9 and further deteriorate cardiac pump function
in CS. We therefore evaluated CPA in patients with CS due
to primary LV failure and sought to determine whether a
reduction of CPA is associated with mortality in this setting.
Methods
The study was approved by our ethical committee (Nr:
2016-01705), as a retrospective use of clinical data with
waiver of consent. Reporting of the study conforms to the
STROBE statement for the report of observational cohort
studies (see Supplemental Material). The cohort included 91
patients hospitalized in our 35-bed tertiary intensive care
unit (ICU), with a diagnosis of CS due to primary LV failure
between 2008 and 2011, monitored with a PAC and an
intra-arterial catheter inserted within 24 h of admission
(among the 91 patients, 64 had the PAC inserted immedi-
ately upon admission, while the remaining 27 patients had
the PAC inserted later within the first 24 h). Patients with CS
due to primary RV failure were excluded. The diagnosis of
CS was based on clinical features, including arterial hypo-
tension requiring vasopressor support in the absence of
hypovolemia, together with signs of systemic hypoperfusion
(low urine output, altered mental status, lactic acidosis, cold
skin and extremities).10
Hemodynamic measurements
All pressure measurements were strictly obtained in the
supine position, at end expiration and with standard zero
reference level at the phlebostatic axis. Pulmonary arterial
pressures (systolic (sPAP), diastolic (dPAP), mean (mPAP),
wedge (PAWP)), central venous pressure (CVP), cardiac
output (CO), mean blood pressure (mean BP), and heart
rate (HR) were stored within our clinical information
system (MetaVision, iMDsoft). The following variables
were calculated: stroke volume (SV¼CO/HR, mL); pul-
monary pulse pressure (PP¼ sPAP-dPAP, mmHg); trans-
pulmonary pressure gradient (TPG¼mPAP-PAWP,
mmHg); diastolic pressure gradient (DPG¼ dPAP-PAWP,
mmHg); pulmonary vascular resistance (PVR¼TPG/CO,
Wood units: mmHg min/L, or mm Hg s/mL); pulmonary
arterial compliance (CPA¼SV/PP, mL/mmHg); time con-
stant (RC time¼CPAPVR, seconds). Data were recorded
for all patients after 24 h. In five nonsurvivors who
died in the first 24 h, values obtained after 12–18 h were
considered as the 24 h time point. An echocardiogram was
performed in most patients in the first 24 h, to visually
estimate LVEF. RV systolic function was qualitatively
reported (‘‘eyeball method’’) as normal function, moderate
dysfunction, or severe dysfunction. The amount of catechol-
amines (dobutamine and norepinephrine) administered was
determined.
Statistical analysis
Continuous variables are expressed as means SD, or med-
ians and interquartile ranges (Q1–Q3). Categorical data are
shown as absolute numbers and percentages. Comparisons
were made between survivors and nonsurvivors (in-hospital
mortality), as well as between patients according to the
severity of RV dysfunction. The normality of distribution
of the continuous data was determined using the Shapiro–
Wilk test, with an alpha level set at 0.05. Since most of
the data displayed a non-normal distribution, univariate
statistical analyses were done using the nonparametric
Wilcoxon’s rank test. The chi-square test was used for
categorical variables. To test the hypothesis of possible asso-
ciations between CPA and certain variables (including
PAWP, age and catecholamine treatment), we performed
bivariate analyses and simple linear regressions, with calcu-
lation of the Pearson r correlation coefficient and r2 deter-
mination coefficient.
To evaluate the possible independent predictive role of
CPA for in-hospital mortality, multiple logistic regression
was applied with mortality as the response binomial variable
and several explanatory variables, including CPA, PVR,
mPAP, sPAP, dPAP, PAWP, and age. Since a minimum
of 10 events per variable should be used to avoid biased
regression coefficients,11 mostly overestimated,12 and given
a number of events (in-hospital deaths) of 25 in our cohort,
we considered to run several logistic regression analyses
with only two co-variables (including CPA and a second
co-variable) at a time. Wald statistics were performed to
test for the significance of each variable in the different
models, and odds ratios with 95% CI were calculated for
each variable. Furthermore, to control for possible type I
error, we introduced a Bonferroni adjustment for assessing
significance in these six models (thus, a p-value of
0.05/6¼ 0.008 was used as the significance limit in these
analyses). The performance of each logistic regression was
evaluated by ROC diagrams and calculation of the area
under the curve (AUC).
A p< 0.05 was considered statistically significant, except
from the multivariate analysis, where a p< 0.05/6¼ 0.008 was
considered significant (Bonferroni adjustment). We used the
JMP statistical software, version 13 for all the analyses.
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Results
The characteristics of patients of the whole cohort (91
patients) are shown in Table 1, while the characteristics of
the 66 survivors and 25 nonsurvivors are shown in Table 2.
Table 3 shows the hemodynamic data at 24 h and the
amount of administered catecholamines (dobutamine and
norepinephrine) during the first 24 h.
As indicated in Fig. 1, a statistically significant correl-
ation was noted between CPA and PAWP (p< 0.05),
whereas there was no significant correlation between CPA
and age, as well as between CPA and catecholamines. As
shown in Fig. 2, for each quartile of CPA (in mL/mm Hg:
Q1: 0.7–1.7; Q2: 1.7–2.6; Q3: 2.6–3.6; Q4: 3.6–6.3), the rela-
tive mortality was 43.5%, 39.1%, 21.7%, and 4.5%, respect-
ively (p¼ 0.008, chi-square test, Fig. 2(a)). We also
determined the time to event (death) for each quartile of
CPA in nonsurvivors (Fig. 2(b)). Although a trend towards
a shorter time to event with lower quartiles of CPA was
noted, it did not reach statistical significance (p¼ 0.27, chi-
square test), which may reflect the small numbers of
observations in each quartile. We did not include the
fourth quartile in the analysis, as there was only one event
(death) in this quartile. PVR vs. CPA graphs showed an
inverse relationship that was shifted to the left in nonsurvi-
vors (Fig. 2(c) to (e)), consistent with a significantly
decreased RC-time (Fig. 2(f)).
In the 64 patients who had the PAC inserted directly
upon admission (49 survivors and 15 nonsurvivors), we cal-
culated the difference of CPA between admission (0 h)
and the 24 h time-point (delta CPA, Table 3). The delta
CPA was positive in survivors (þ0.8 1.3mL/mm Hg), but
negative in nonsurvivors (0.1 1.0mL/mm Hg, p¼ 0.03
between groups). The individual data of CPA at 0 h (base-
line) and 24 h are shown in Fig. 3. At 0 h, CPA
was 2.5 1.4mL/mm Hg in the 49 survivors and
1.8 0.8mL/mmHg in the 15 nonsurvivors (p¼ 0.07
between groups, Fig. 3(a)), and at 24 h, it reached
3.3 1.4mL/mm Hg in survivors and 1.7 0.7mL/mm Hg
in nonsurvivors (p< 0.001). The individual trends of CPA
(Fig. 3(b)) indicate that, in the 49 survivors, CPA increased
in 38 patients, decreased in 8 and remained stable in 3, while
in the 15 nonsurvivors, CPA increased only in 8 patients,
but decreased in 7.
Table 2. Demographic and clinical characteristics for survivors and
nonsurvivors.
Variables Survivors Nonsurvivors p-Value
n (%) 66 (73) 25 (27)
Age, mean SD 65 (11) 75 (10) 0.001
SAPS II, mean SD 36 10 44 12 0.001
Male, n (%) 50 (68) 18 (72) 0.7
ICU LOS (d), median (Q1–Q3) 10 (6–20) 4 (1–7) <0.001
Hospital LOS (d), median
(Q1–Q3)
28 (15–43) 6 (2–17) <0.001
LVEF (%), mean SDb 29 12 24 11 0.09
IABP, n (%) 30 (45) 14 (56) 0.4
Urgent coronary angiography,
n (%)
36 (55) 14 (56) 0.9
Invasive mechanical ventilation,
n (%)
57 (86) 18 (72) 0.1
Invasive ventilation (h),
median (Q1–Q3)




42 (64) 21 (84) 0.1
Valvular disease, n (%) 10 (15) 1 (4) 0.2
Arrhythmia, n (%) 0 (0) 2 (8) <0.05
Dilated cardiomyopathy, n (%) 4 (6) 1 (4) 0.6
Others,a n (%) 10 (15) 0 (0) <0.05
Arterial pH (admission),
mean SD
7.26 0.14 7.30 0.10 0.17
Arterial lactate (mmol/L),
mean SD
4.4 4.0 4.8 3.3 0.25
aOthers are as given in Table 1.
bEchocardiography was obtained in the first 24 h. LV EF was not reported in
nine patients (four survivors and five nonsurvivors). Univariate analysis.
Wilcoxon’s rank test (continuous variables), chi-square test (categorical
variables).
APACHE: acute physiology and chronic health evaluation; ICU: intensive care
unit; IQR: interquartile range; LOS: length of stay; LVEF: left ventricle ejection
fraction; SAPS: simplified acute physiology score.
Table 1. Study population characteristics.
Patients, n 91
Age (yr), mean SD 67 11
Male, n (%) 68 (74)
APACHE II score, mean SD 22 5
SAPS II score, mean SD 38 11
Admission arterial blood lactate (mmol/L) 4.5 3.8
In-hospital mortality, n (%) 25 (27)
ICU LOS (d), median (Q1–Q3) 9 (4–14)
Hospital LOS (d), median (Q1–Q3) 23 (11–36)
Invasive mechanical ventilation, n (%) 75 (82)
Urgent coronary angiography, n (%) 50 (60)
LVEF (%), mean SDb 27 12
Etiology of CS
Acute coronary syndrome, n (%) 63 (69)
Valvular disease, n (%) 11 (12)
Arrhythmia, n (%) 2 (2)
Terminal dilated cardiomyopathy, n (%) 5 (6)
Others,a n (%) 10 (11)
aOthers are: myocarditis (n¼ 2), drug toxicity (n¼ 2), thyreotoxicosis (n¼ 1),
post CPB (n¼ 2), sepsis (n¼ 2), obstructive cardiomyopathy (n¼ 1).
bLVEF was not reported in nine patients (four survivors and five nonsurvivors).
APACHE: acute physiology and chronic health evaluation; ICU: intensive care
unit; IQR: interquartile range; LOS: length of stay; LVEF: left ventricle ejection
fraction; SAPS: simplified acute physiology score.
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Figure 4 presents the results of the qualitative assessment
of RV systolic function. In survivors and nonsurvivors,
respectively, RV function was reported as normal (38 vs.
29%), moderate dysfunction (33 vs. 9%), and severe
dysfunction (29 vs. 62%), the differences being significant
(p¼ 0.01, chi-square test, Fig. 3(a)). Values of PAWP
(Fig. 3(b)), CVP (Fig. 3(c)), and PVR (Fig. 3(d)) did not
statistically differ between patients with or without RV dys-
function, while patients with the most severe forms of RV
dysfunction displayed significantly lower CPA (Fig. 3(e),
Wilcoxon’s rank test).
Table 4 shows the results of the multiple logistic regres-
sion analyses. CPA was independently associated with mor-
tality, whatever pulmonary hemodynamic variable or age
was introduced in the model. For each CPA increase of
1mL/mm Hg, odds ratios for mortality remained stable
and below unity whatever the covariate in the model. For
the different regressions, calculated AUC were the follow-
ing: 0.8 (CPA and PVR); 0.77 (CPA and sPAP); 0.76 (CPA
and dPAP); 0.77 (CPA and mPAP); 0.85 (CPA and PAWP);
and 0.86 (CPA and age).
Discussion
In this retrospective cohort of 91 patients with CS due to
primary LV failure, CPA determined 24 h upon hospital
admission as an indicator of RV pulsatile afterload,
was significantly associated with mortality. The prognostic
significance of CPA contrasted with the lack of association
between usual measures of pulmonary hemodynamics
(including sPAP, dPAP, mPAP, DPG, TPG, and PVR)
and mortality.
The assessment of pulmonary hemodynamics offers
essential information with respect to RV afterload, but
such information has been generally overlooked in the
evaluation of CS. The pulmonary hydraulic load comprises
both a steady (estimated by PVR) and an oscillatory (esti-
mated by CPA) components, which make up most of the
afterload of the RV.5,13 The RV must therefore generate
sufficient hydraulic power to produce steady (mean power)
and pulsatile (oscillatory power) flows, in order to remain
adequately ‘‘coupled’’ to the pulmonary circulation (concept
of RV-PA coupling).14 The pulsatile component repre-
sents 25% of the total hydraulic power of the RV, in con-
trast to the 10% spent by the LV to maintain pulsatile flow
within the systemic circulation,13 which implies that the RV
wastes much of its energy just to create vascular pulsation,
and may thus be particularly affected by a reduction in CPA,
increasing its oscillatory load.15 The latter assertion has
been supported by a series of studies indicating that a
reduced CPA detrimentally impacts the RV and is a strong
and independent predictor of mortality in patients with pre-
capillary pulmonary hypertension (PH).6,15 These studies
also confirmed a remarkable property of the pulmonary
Table 3. Hemodynamic data and catecholamine treatment at 24 h in survivors and nonsurvivors.
Variables Survivors Nonsurvivors p-Value
Mean blood pressure (mm Hg) 72 7 72 7 0.3
Heart rate (beats/min) 97 20 98 16 0.7
Cardiac index (mL/min/m2) 2.5 0.6 2.0 0.6 <0.001
Stroke volume (mL) 52 18 37 13 <0.001
Central venous pressure (mm Hg) 13 4 14 5 0.2
Pulmonary artery wedge pressure (mm Hg)b 17 5 22 5 <0.001
Systolic pulmonary pressure (mm Hg) 41 10 47 14 0.05
Diastolic pulmonary pressure (mm Hg) 23 5 26 7 0.05
Mean pulmonary pressure (mm Hg) 29 7 33 8 0.11
Pulmonary pulse pressure (mm Hg) 18 7 21 9 0.13
Transpulmonary gradient (mm Hg) 12 6 11 6 0.5
Diastolic pressure gradient (mm Hg) 6 4 4 5 0.1
Pulmonary vascular resistance (Wood units) 2.7 1.4 3.2 1.8 0.3
Pulmonary arterial compliance (mL/mm Hg) 3.2 1.4 2.0 0.8 <0.001
Delta pulmonary arterial compliance (mL/mm Hg)a 0.8 1.3 –0.1 1.0 0.03
Pulmonary artery time constant (s) 0.45 0.20 0.32 0.13 0.002
Dobutamine 0–24 h (mg/kg) 3.2 (0.1–7.7) 4.2 (1.5–7.0) 0.27
Norepinephrine 0–24 h (mg/kg) 0.23 (0.05–0.48) 0.32 (0.06–0.7) 0.6
Hemodynamic variables at 24 h were available for all patients (in five nonsurvivors, values obtained at 12–18 h instead of 24 h were computed).
aDelta pulmonary arterial compliance (the difference in pulmonary arterial compliance between values on admission and at 24 h) was calculated in the subset of
patients who had the PAC inserted directly upon admission (n¼ 64 patients, including 49 survivors and 15 nonsurvivors).
All data are mean SD, except for dobutamine and norepinephrine, expressed in medians (Q1–Q3). Univariate analysis. Wilcoxon’s rank test.
bPAWP could not be obtained in seven survivors and three nonsurvivors.
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circulation, initially highlighted by Lankhaar et al.,14 which
is that of a tight inverse hyperbolic relationship between CPA
and PVR, so that their product (the time constant, or RC-
time, of the pulmonary circulation) remains constant during
the course of various forms of pre-capillary PH. This implies
that the measurements of PVR and CPA are somewhat
redundant, as the knowledge of one of these variables
allows the derivation of the other.16
The situation is different in the context of left heart (LH)
dysfunction, where the passive increase of pulmonary pres-
sure due to elevated LV filling pressure causes the pulmon-
ary circulation to become stiffer in virtue of the nonlinear
stress–strain relationship.16 In a large database of patients
with CHF, Tedford et al.7 could thus demonstrate that an
elevation of PAWP produced a significant decrease of CPA,
which was associated with a reduced RC-time, contrasting
with the constant RC-time reported in other forms of PH.7
Similar findings have been reported in large cohorts of CHF
patients by other investigators as well.17,18 These findings
imply that, at any value of PVR, an increase in PAWP pro-
duces a greater reduction of CPA and promotes a significant
elevation of RV pulsatile afterload.19 Thus, the calculation
of CPA in patients with LH diseases provides important
information, which is not obtained by the simple calculation
of PVR. Indeed, reduced CPA in the course of CHF is
strongly related to RV dysfunction and is a potent predictor
of poor long-term prognosis.18
Our current data provide further insights into the prog-
nostic importance of CPA in the setting of LH failure. We
show for the first time that a reduction of CPA occurs also in
the very acute condition of CS, and that such reduction is
significantly correlated with the short term mortality of CS.
At CPA values< 1.7mL/mmHg, mortality reached 43.5%,
whereas at CPA values> 3.6mL/mm Hg, mortality was
only 4.5%. There was a significant inverse correlation
between PAWP and CPA, which supports the notion that
passive upstream transmission of elevated PAWP increases
the stiffness of the pulmonary circulation, in accordance
with the pressure-dependence of pulmonary vascular com-
pliance.16 The reduction of CPA was associated with a left-
ward shift of the CPA–PVR relationship and a significant
shortening of the pulmonary RC-time in nonsurvivors,
which raises the hypothesis that an increased RV oscillatory
load may represent a critical event precipitating death in the
context of CS.
In multivariate analysis, CPA was the only significant pre-
dictive variable of poor outcome, contrasting with the lack
of predictive ability of other hemodynamic pulmonary
Fig. 1. Correlations between pulmonary artery compliance, wedge pressure, age, and catecholamines. Influence of pulmonary artery wedge
pressure (PAWP, a), age (b), norepinephrine (c), and dobutamine (d) treatment on pulmonary artery compliance (CPA) in patients with
cardiogenic shock. Regression lines (in red) and r2 determination coefficients are shown for each correlation.
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variables including sPAP, dPAP, mPAP, and PVR. This
observation is in line with a recent study by Tampakakis
et al.20 in CHF patients with post-capillary PH, who
reported that CPA, as well as pulmonary arterial effective
elastance, a global indicator of RV afterload, predicted mor-
tality in a more consistent way than PVR and TPG. It is also
noteworthy that CPA remained significantly associated with
mortality when using PAWP as a covariate, implying that
reduced CPA is an independent predictor of mortality and
not simply a surrogate indicator of increased PAWP in CS.
It appears therefore that CPA is a critical determinant of
outcome in patients with a spectrum of LV dysfunction
ranging from chronic stable disease to acute circulatory
shock. In the latter setting, a reduction of CPA would be
expected to be especially detrimental, since the nonadapted
RV is unable to sustain a brisk increase in afterload.
Furthermore, in the context of acute LV systolic dysfunc-
tion, the systolic performance of the RV is expected to be
indirectly depressed, through reduced systolic interactions
between the two ventricles.21 The concomitant acute
increase of RV pulsatile afterload and decrease of RV sys-
tolic performance would therefore precipitate RV-PA
uncoupling,22 hence rapidly amplifying the severity of the
acute circulatory failure, with a negative prognostic impact,
a working hypothesis which is graphically depicted in Fig. 5.
Such hypothesis was substantiated by the significantly lower
CPA noted in patients with more severe RV dysfunction and
the higher percentage of nonsurvivors with severe RV dys-
function. Therefore, it is possible that an increased RV after-
load related to reduced CPA in patients with CS may
promote a right heart failure phenotype with worse
prognosis.
A noticeable finding of our study was that survivors dis-
played, on average, a positive trend of CPA between admis-
sion and at 24 h, whereas such a trend was absent in
nonsurvivors. Although such analysis was restricted to
Fig. 2. Pulmonary artery compliance and time constant in survivors and nonsurvivors of cardiogenic shock. (a) Mortality (in percent of patients)
according to quartiles of pulmonary artery compliance at 24 h (in mL/mm Hg: 1st Q¼ 0.7–1.7; 2nd Q¼ 1.7–2.6; 3rd Q¼ 2.6–3.6; 4th Q¼ 3.6–
6.5). (b) Time to death in nonsurvivors, according to the quartile of CPA (Whiskers represent medians with Q1, Q3, and min/max values). A
nonsignificant trend was noted for a shorter time to death with lower CPA quartiles (the 4th quartile of CPA was not included in the analysis, as
there was only one death in this quartile). (c–e) Pulmonary vascular resistance (PVR) vs. compliance (CPA) diagrams in survivors (c) and
nonsurvivors (d). Fused diagram (e) shows the leftward shift of the curve in nonsurvivors. Curves display the power function fitting of the PVR–
CPA relationships. CPA units are mL/mm Hg; PVR units are mmHg s/mL. (f) Time-constant (RC-time) of the pulmonary circulation in survivors
and nonsurvivors (dots: individual values; horizontal bars: mean values). Statistics: (a,b) Chi-square test. (f) Wilcoxon’s rank test.
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patients with available hemodynamic data on admission (49
survivors and 15 nonsurvivors), this result suggests that rais-
ing CPA could represent a therapeutic target in patients with
CS. This could be achieved by a more aggressive treatment
of elevated LV filling pressures, as pointed out by Dupont
et al.18 in patients with decompensated CHF. Whether other
therapeutic strategies could be implemented to specifically
increase CPA is unknown.
6 In patients with PAH, prosta-
noids increased CPA and improved RV function,
23 but such
information is lacking in patients with PH due to LH dis-
eases. Positive results of inhaled pulmonary vasodilators
(including NO and prostanoids) have been reported in
patients with acute RV dysfunction following LV device
implantation and cardiac transplantation (reviewed in
Sabato et al.24), but the influence of these drugs on CPA
has not been determined. In addition, the use of inhaled
vasodilators in patients with elevated LV filling pressure
may be limited by the risk of promoting lung edema.25
Therefore, additional studies are needed to specifically
address this issue.
It must be underscored that nonsurvivors were signifi-
cantly older than survivors, which could represent a con-
founding factor in the interpretation of the prognostic
value of CPA, as the latter may slightly decrease with
age.6,7 However, this possibility is not supported by our
data, owing to the lack of significant correlation between
age and CPA, and by the finding that CPA remained inde-
pendently associated with mortality in a model incorporat-
ing age as a covariate. Also, we might consider that
differences in CPA between survivors and nonsurvivors
could reflect differences in the amount of catecholamines
administered. Indeed, there is experimental evidence of a
reduction of CPA by alpha-adrenergic catecholamines,
26
and of an increase of CPA by the beta-adrenergic
Fig. 3. Variation of pulmonary artery compliance between admission and 24 h. (a) Individual values of CPA in the 64 patients who had the PAC
inserted directly upon admission (49 survivors, red squares, and 15 nonsurvivors, black dots), at 0 h (baseline) and 24 h. The dotted lines connect
the mean values at 0 h and 24 h in survivors (red) and nonsurvivors (black). Statistical differences between survivors and nonsurvivors at 0 h and
24 h are indicated (Wilcoxon’s rank test). (b) Individual trends of CPA between 0 h (baseline) and 24 h in 49 survivors (left) and 15 nonsurvivors
(right) with the PAC inserted directly on admission.
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dobutamine.27 We neither noticed any significant differences
in the amount of catecholamines given to survivors and
nonsurvivors, nor did we find any correlations between cat-
echolamine therapy and CPA. We can therefore reasonably
rule out any confounding effect of therapies on the observed
differences of CPA.
Our study has several limitations, including its retro-
spective design and limited number of patients included.
However, it must be noted that the incidence of CS is
relatively low, with a trend towards progressive reduction
over time,28 and a similar trend in the use PA catheter
monitoring.29 Therefore, the recruitment of a relatively
small number of patients is a frequent problem in studies
dealing with CS and invasive hemodynamic monitoring.30
Another limitation is the lack of quantitative echographic
data on RV systolic function. In our cohort, echocardiog-
raphy was performed on an urgent basis with the primary
aim to assess the LV. RV systolic function was therefore
simply qualitatively assessed (‘‘eyeball’’ method), which
has known limitations when compared with quantitative
assessment.31 Future studies addressing the prognostic
influence of CPA in CS should therefore include a precise,
quantitative, evaluation of the RV consequences of
depressed CPA.
In conclusion, our study shows that a reduced CPA
adversely affects the outcome of CS due to primary LV dys-
function. The prognostic significance of CPA contrasted with
the lack of predictive ability of usual measures of pulmonary
hemodynamics, including PVR. Reduced CPA was asso-
ciated with more severe RV systolic dysfunction, which
was associated with mortality in our cohort. These findings
indicate that an increased RV pulsatile afterload due to
decreased CPA is a critical event in CS. We propose that
the estimation of CPA should be part of the hemodynamic
monitoring of CS, and that increasing CPA should be eval-
uated as a therapeutic target in this setting.
Fig. 4. Hemodynamic variables according to the severity of right ventricle systolic dysfunction. (a) Severity of RV dysfunction in survivors and
nonsurvivors (0: no dysfunction; 1: moderate dysfunction; 2: severe dysfunction). Values of PAWP (b), CVP (c), PVR (d), and CPA (e) according
to RV dysfunction (dots: individual values; horizontal bars: mean values). Statistics: (a) Contingency analysis, chi-square test. (b–e) Wilcoxon’s
rank test.
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Fig. 5. Proposed role of reduced pulmonary artery compliance in cardiogenic shock. A triggering factor such as cardiac ischemia leads to severe
left ventricle (LV) systolic dysfunction (orange arrow), with subsequent low cardiac output (CO) and cardiogenic shock. The triggering factor may
also affect the right ventricle (RV) (orange dotted arrow). LV dysfunction is associated with increased LV filling pressure, which is passively
transmitted to the upstream pulmonary circulation, in turn increasing the stiffness of the pulmonary artery (PA), reducing PA compliance and
shortening the PA time constant (black arrows). As a result, RV pulsatile afterload is increased, leading to RV–PA uncoupling and RV systolic
dysfunction, which promotes further reduction of CO and amplifies acute circulatory failure (red arrows). RV–PA uncoupling may be exacerbated
by the depressed RV systolic function due to reduced systolic interaction linked to LV systolic dysfunction.
Table 4. Predictive value of pulmonary artery compliance for mor-
tality of cardiogenic shock.
Odds ratio 95% CI p-Value*
Predictor
CPA 0.21 0.09–0.54 <0.001
PVR 0.67 0.41–1.08 0.09
CPA 0.37 0.19–0.68 <0.001
mPAP 0.99 0.92–1.07 0.82
CPA 0.32 0.16–0.66 <0.001
sPAP 0.98 0.93–1.03 0.47
CPA 0.39 0.22–0.71 <0.001
dPAP 1.02 0.93–1.11 0.74
CPA 0.39 0.20–0.75 0.004
PAWP 1.22 1.06–1.39 0.004
CPA 0.31 0.14–0.57 0.001
Age 1.12 1.06–1.19 <0.001
CI: confidence interval. Odds ratio are calculated for one unit change for each
variable (1 mmHg for mPAP, sPAP, dPAP, and PAWP, 1 y for age, 1 WU for PVR;
1 mL/mm Hg for CPA).
CPA: pulmonary artery compliance; dPAP: diastolic pulmonary artery pressure;
mPAP: mean pulmonary artery pressure; sPAP: systolic pulmonary artery pres-
sure; PAWP: pulmonary artery wedge pressure; PVR: pulmonary vascular
resistance.
*p-Values less than 0.008 were deemed significant, after the Bonferroni
adjustment.
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